跳至主要内容
临床试验/NCT06386289
NCT06386289撤回不适用

Safety, Performance and Lesion Evaluation of Neurothrombectomy Using CEREGLIDE 92 Intermediate Catheter: A Prospective Multi-Center Single-Arm IDE Trial (SPLENDID)

Cerenovus, Part of DePuy Synthes Products, Inc.0 个研究点目标入组 140 人开始时间: 2025年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
入组人数
140
主要终点
First pass reperfusion

研究概览

简要总结

The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of acute ischemic stroke.
  • Baseline mRS ≤ 2
  • Completed informed consent.

排除标准

  • Known pregnancy.
  • Life expectancy less than 90 days prior to stroke onset.
  • Known Diagnosis of Dementia
  • Treatment with heparin within 48 hours.
  • Clinical history, past imaging or clinical judgement suggest that the intracranial occlusion is chronic.
  • Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.
  • Baseline CT or MRI showing mass effect
  • Concurrent sino-venous thrombosis
  • Currently participating in an investigational (drug, device, etc.) clinical trial, excluding trials in observational, natural history, and/or epidemiological studies not involving intervention and that will not confound study endpoints. Sponsor approval is required.

结局指标

主要结局

First pass reperfusion

时间窗: Intraprocedural

First pass reperfusion (eTICI ≥ 2b50 without additional therapy)

次要结局

未报告次要终点

研究者

发起方
Cerenovus, Part of DePuy Synthes Products, Inc.
申办方类型
Industry
责任方
Sponsor

相似试验